Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...

Québec City, April 14, 2023 - Fuchs' endothelial corneal dystrophy, a degenerative eye disease, causes progressive vision loss that can induce blindness. It is the leading cause of corneal ...

In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, ...

Fuchs’ dystrophy is an eye condition that causes the death of cells in the inner lining of the cornea. This may lead to the accumulation of fluid in the cornea and negatively affect vision. One of the ...

DUBLIN--(BUSINESS WIRE)--The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, 2025-2035" report ...

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...